Loading viewer...
investor_presentation
Format: PDF investor_presentation
MindMed presented Phase 2b topline data for MM120, its proprietary lysergide D-tartrate candidate for generalized anxiety disorder, along with ODT pharmacokinetic bridging study results. The presentation highlighted the drug's breakthrough therapy designation and clinical progress as of March 2024.
investor_presentation
23 Pages
investor_presentation
30 Pages
Elevation Oncology
Terran Orbital Investor Presentation August 2023
investor_presentationinvestor_presentation
25 Pages
Terran Orbital Corporation